The effect of in vivo SCH 14988 treatment on blood neutrophil levels is similar to that of hG-CSF treatment in CY-dosed mice. BALBc/J were dosed with CY on day 0 (except for normal, age-matched) and daily administration with hG-CSF or SCH 14988 begun on day 1. Mice were sacrificed on day 6 and analyzed as described in Fig 4 legend. Data represent mean ± SEM and are representative of three separate experiments. The differences between the PBS/NMS and G-CSF treatment groups, and between the CMC and SCH 14988 treatment groups is statistically significant at P < .01 as determined by the Students' t-test. The differences between the SCH 14988 and the 50- and 125-μg/kg human G-CSF treatment groups are also statistically significant at P < .05. Cytological examination confirmed that granulocytes were exclusively segmented neutrophils.